+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07626411

Assessment of Stroke and Systemic Embolism Prevention with REGN7508 Compared to Apixaban in Adults with Atrial Fibrillation

Led by Regeneron Pharmaceuticals · Updated on 2026-10-26

15364

Participants Needed

54

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an experimental drug called REGN7508, a monoclonal antibody against Factor XI, compared to apixaban in adults with atrial fibrillation, a condition where the heart beats too fast and irregularly. The study aims to assess the safety and effectiveness of REGN7508 in preventing stroke and systemic embolism. Other aspects include monitoring side effects and whether the body produces antibodies against REGN7508. Participants will be randomly assigned to receive either REGN7508 plus placebo or apixaban plus placebo. Both treatments are given according to the study protocol. This Phase 3, double-blind trial includes two groups running in parallel. The study spans approximately 36 months, during which participants take the assigned treatment and are regularly monitored. During the trial, participants will attend scheduled visits for assessments including monitoring for strokes, systemic embolism, bleeding events, and adverse reactions. Researchers will also check for the presence and levels of anti-drug antibodies against REGN7508. The primary outcomes focus on the time to first stroke or systemic embolism and bleeding events over about three years. Safety and effectiveness will be closely observed throughout the study duration.

CONDITIONS

Brief Title

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here